PET/MR Imaging for Pulmonary Hypertension
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment PET/MR with 18F-FDG for pulmonary hypertension?
PET/MRI with 18F-FDG is a promising tool for diagnosing and monitoring heart-related conditions, as it combines detailed images of the body's structure with information about how tissues are functioning. This approach has shown potential in assessing heart diseases and could help in understanding and managing pulmonary hypertension by providing comprehensive insights into heart and lung function.12345
Is PET/MR Imaging with 18F-FDG safe for humans?
How is the PET/MR with 18F-FDG treatment different from other treatments for pulmonary hypertension?
What is the purpose of this trial?
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
Research Team
Patrick Veit-Haibach, MD
Principal Investigator
University Health Network, Toronto
Eligibility Criteria
This trial is for adults over 18 with a diagnosed thoracic cancer intended to be treated with radiotherapy that also affects the heart. They must consent to PET/MR imaging, blood tests, and not be pregnant if of child-bearing age.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-Radiotherapy Assessment
PET/MR scans and metabolomic markers assessment conducted 4 weeks prior to radiotherapy
Radiotherapy
Participants undergo radiotherapy treatment for thoracic cancer
Post-Radiotherapy Assessment
PET/MR scans and metabolomic markers assessment conducted 6-10 weeks after completion of radiotherapy
Follow-up
Participants are monitored for changes in FDG uptake and cardiopulmonary function up to 16 weeks after radiotherapy
Treatment Details
Interventions
- PET/MR with 18F-FDG
PET/MR with 18F-FDG is already approved in European Union, United States, Canada, Japan for the following indications:
- Diagnostic imaging for various cancers and conditions, including pulmonary hypertension
- Diagnostic imaging for various cancers and conditions, including pulmonary hypertension
- Diagnostic imaging for various cancers and conditions, including pulmonary hypertension
- Diagnostic imaging for various cancers and conditions, including pulmonary hypertension
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor